Scott A. Byrd insider trades: Cadence Pharmaceuticals (CADX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 2, 2013 | CADX | ↓ Sell | 7,812 | $9.16 | $72K | Direct | Dec 3, 2013 (1d) |
| Nov 15, 2013 | CADX | ↓ Sell | 10,416 | $8.00 | $83K | Direct | Nov 18, 2013 (3d) |
| Jun 7, 2013 | CADX | ↓ Sell | 67,115 | $7.53 | $505K | Direct | Jun 11, 2013 (4d) |
| May 10, 2011 | CADX | ↑ Buy | 2,000 | $7.22 | $14K | Direct | May 11, 2011 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Scott A. Byrd's insider trades
Scott A. Byrd is SVP, Chief Commercial Officer at Cadence Pharmaceuticals (CADX). Since May 10, 2011, Scott has reported 1 open-market purchase worth $14K and 3 sales worth $660K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), option exercises (3 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CADX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.